A deep dive into Shilpa Medicare Limited (SHILPAMED) — examining the financials, valuation picture, and who owns the stock.
Shilpa Medicare Revenue Trend
Shilpa Medicare Limited managed to grow its top line 11.7% in FY2025, with revenue hitting ₹1,286 Cr.
Shilpa Medicare Limited's revenue compounded at 7.7% over 10 years — not a breakout compounder, but steady enough to suggest a stable business.
At ₹1,286 Cr in annual revenue, Shilpa Medicare Limited is one of the mid-sized players in the pharmaceuticals space.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,286 Cr | +11.7% |
| FY2024 | ₹1,152 Cr | +9.7% |
| FY2023 | ₹1,050 Cr | -8.3% |
| FY2022 | ₹1,146 Cr | +23.0% |
| FY2021 | ₹931 Cr | — |
View Shilpa Medicare Limited's full 10-year revenue trend with CAGR analysis →
Shilpa Medicare Profitability
Shilpa Medicare Limited delivered net profit of ₹78.3 Cr in FY2025, a solid 145.6% jump from ₹31.9 Cr in FY2024.
Net profit margin improved to 6.1% in FY2025 from 2.8% in FY2024, indicating better cost control.
The diluted EPS figure moved up to ₹4.02 in FY2025, against ₹1.84 posted in FY2024.
Is Shilpa Medicare Undervalued
Shilpa Medicare Limited shares are currently trading at ₹623.55.
Craytheon calculates intrinsic value using the P/E Ratio and EPS Growth models. Both appear in the Valuation Models cards below.
Valuation Models
Shilpa Medicare Shareholding Pattern
Promoter stake dipped to 40.1% from 44.2% over 4 quarters — something to monitor.
FII ownership stands at 11.4%, up from the 10.9% recorded a year ago.
Domestic investors held 8.1% of the company as of June 2026, up year-over-year from 7.7%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 40.1% | 11.4% | 8.1% | 40.4% |
| Mar 2026 | 40.1% | 11.1% | 8.6% | 40.2% |
| Dec 2025 | 40.1% | 11.0% | 8.3% | 40.6% |
| Sep 2025 | 44.2% | 10.9% | 7.7% | 37.2% |
Track quarterly shareholding changes for Shilpa Medicare Limited →
Shilpa Medicare Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹33.11B at the end of FY2025, up 7.0% from ₹30.93B a year earlier.
Property, Plant & Equipment is the largest block at 49.8%, followed by Other Assets at 18.3% and Receivables at 13.3%.
Equity makes up 71.4% of liabilities and equity, with debt at 17.8% and operating liabilities at 10.9%. Over the year, debt is down 37.3% and equity is up 31.3%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 259.68M |
| Receivables | 4.41B |
| Inventories | 3.48B |
| Property, Plant & Equipment | 16.49B |
| Investments | 345.39M |
| Intangibles & Goodwill | 2.05B |
| Other Assets | 6.07B |
| Category | Value |
|---|---|
| Equity | 23.64B |
| Short-term Debt | 3.55B |
| Long-term Debt | 2.33B |
| Trade Payables | 953.82M |
| Other Liabilities | 2.64B |
Shilpa Medicare at a Glance
In summary, Shilpa Medicare Limited (SHILPAMED) presents the following picture for fundamental analysts.
Revenue of ₹1,286 Cr in FY2025, up 11.7% year-over-year.
Long-term revenue has been compounding at 7.7% annually over 10 years.
The company is profitable, with a net margin of 6.1% and net income of ₹78.3 Cr.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Shilpa Medicare Limited.